APUS

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

MATAWAN, New Jersey / GEORGE TOWN, Cayman Islands, Aug. 03, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("MindWave Innovations Inc." or the "Company"), today announced that its NILA token is now available to eligible users in the United States on Webot, a licensed U.S. cryptocurrency exchange. Starting today, eligible U.S. users may access NILA on a licensed American platform for the first time. For anyone new to NILA, this makes it simpler to get started. Eligible users may access the token through a U.S. exchange that operates under applicable licenses, ahead of NILA moving to its own network, M

MATAWAN, New Jersey, and GEORGE TOWN, Cayman Islands, July 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("MindWave Innovations Inc" or the "Company"), today announced MindChain, the world's first fully insured blockchain. MindChain is an insured, production-grade, EVM-compatible Layer 2 network that will go live in October 2026. It gives the MindWave ecosystem its own network, run by its own sequencer and validator set, while every transaction settles on Ethereum for final security. The Company also announced that the NILA token will be available to the U.S. market on Webot beginning Aug. 3,

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

NT 10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

Trading Expected to Resume on NYSE American on Tuesday, May 5 Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the "Inscobee Parties"), resolving all outstanding disputes arising from the APUS' December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company's previously disclosed $100 million PIPE financing, and the advancement of Lōkahi Therapeutics, Inc. as an independent biopharmaceutical company focused on the Apitox program. APUS' common stock is expected to resume trading on the NYSE American on Tuesday, May 5, 20

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

10-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

425 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Subject)

8-K/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

NT 10-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

Rejects Allegations of MindWave Innovations, Inc. SEOUL, South Korea, March 25, 2026 (GLOBE NEWSWIRE) --  Inscobee Inc. ("Inscobee") and Apimeds, Inc., ("Apimeds Korea") today announced that on March 20, 2026, Inscobee and Apimeds Korea, together with other stockholders of Apimeds Pharmaceuticals US, Inc. (the "Company") (NYSE:APUS) who beneficially own at least 66 2/3% of the voting power of the Company, delivered an action by written consent of the stockholders to the Company (the "Written Consent") to remove Elona Kogan, Jakap Koo, Carol O'Donnell and Dr. Bennett Weintraub as directors of the board of directors of the Company, effective immediately. In addition, pursuant to the Written

MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. ("APUS" or the "Company") (NYSE:APUS), today announced that on March 20, 2026, Inscobee Inc. (KS:006490) and its wholly owned subsidiary Apimeds Inc. (together, "Inscobee"), in concert with certain other stockholders, filed an Amendment No. 2 to Schedule 13D with the Securities and Exchange Commission purporting to effect a hostile takeover of the Company's Board of Directors by written consent. Inscobee claims to have removed all four sitting directors of APUS and installed three hand-picked replacements without notice to the Company, without authorization from the Company as

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

425 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Subject)

8-K/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026. The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development